Stock Fundamentals

Company Information

Company Name
Nkarta Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US65487U1088
CIK: 0001787400
CUSIP: 65487U108
Currency: USD
Full Time Employees: 108
Phone: 925 407 1049
Fiscal Year End: December
IPO Date: Jul 10, 2020
Description:

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Address:

1150 Veterans Boulevard, South San Francisco, CA, United States, 94080

Directors & Officers

Name Title Year Born
Mr. Paul J. Hastings CEO & Director 1960
Dr. Nadir Mahmood Ph.D. President and Principal Accounting & Financial Officer 1980
Dr. Shawn Rose M.D., Ph.D. Chief Medical Officer and Head of Research & Development NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Jan 15, 2026 Nadir Mahmood N/A Sale 5.65K $2.07 $11.69K
Jan 15, 2026 Paul J Hastings N/A Sale 26.05K $2.07 $53.92K

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
RA Capital Management, LLC 10.81M Mar 31, 2026 15.10% $0.24 0.00%
BlackRock Inc 4.51M Mar 31, 2026 6.30% $0.00 9.56%
NEA Management Company, LLC 3.57M Mar 31, 2026 4.99% $0.43 0.00%
Samsara BioCapital, LLC 3.51M Mar 31, 2026 4.90% $0.72 0.00%
SR ONE CAPITAL MANAGEMENT, LP 3.33M Dec 31, 2025 4.66% $0.87 0.00%
GSK PLC 3.15M Mar 31, 2026 4.40% $1.11 0.00%
Vanguard Group Inc 2.60M Dec 31, 2025 3.63% $0.00 4.24%
Monaco Asset Management 2.52M Mar 31, 2026 3.52% $0.98 -0.98%
Alyeska Investment Group, L.P. 2.08M Mar 31, 2026 2.91% $0.01 0.00%
Two Sigma Investments LLC 2.05M Mar 31, 2026 2.86% $0.00 110.64%
Vanguard Capital Management, LLC 2.01M Mar 31, 2026 2.81% $0.00 0.00%
Citadel Advisors Llc 1.78M Mar 31, 2026 2.49% $0.00 32.62%
Renaissance Technologies Corp 1.73M Mar 31, 2026 2.42% $0.01 1.78%
Wasatch Advisors LP 1.58M Mar 31, 2026 2.21% $0.02 0.10%
TANG CAPITAL MANAGEMENT LLC 1.48M Mar 31, 2026 2.07% $0.16 0.00%
Geode Capital Management, LLC 1.27M Mar 31, 2026 1.77% $0.00 9.84%
Acadian Asset Management LLC 1.26M Mar 31, 2026 1.76% $0.00 25,688.66%
State Street Corp 1.24M Mar 31, 2026 1.73% $0.00 5.83%
Awm Investment Company Inc 906.00K Mar 31, 2026 1.27% $0.21 0.00%
Peapod Lane Capital LLC 676.21K Mar 31, 2026 0.95% $1.15 0.00%

Shares Statistics

Shares Outstanding: 71.55M
Shares Float: 60.44M
% Insiders: 488.10%
% Institutions: 8,074.70%
Short % Float: 5.91%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Wasatch Ultra Growth 1.49M 2.08% ▲ 0.00% Mar 31, 2026
2 Vanguard Total Stock Mkt Idx Inv 1.42M 1.98% ▲ 0.00% Apr 30, 2026
3 iShares Russell 2000 ETF 1.17M 1.63% ▲ 0.93% May 29, 2026
4 Vanguard Institutional Extnd Mkt Idx Tr 575.34K 0.80% ▲ 3.19% Apr 30, 2026
5 JPM Thmtcs Gentc Thrps C2 dist USD 558.45K 0.78% ▲ 0.59% Apr 30, 2026
6 Fidelity Small Cap Index 456.80K 0.64% ▲ 9.65% Mar 31, 2026
7 iShares Russell 2000 Value ETF 415.69K 0.58% ▲ 0.00% May 29, 2026
8 State St Russell Sm/Mid Cp® Indx SL Cl I 362.59K 0.51% ▲ 0.00% May 31, 2026
9 Russell 2000 Equity Index Fund B 355.78K 0.50% ▼ 0.04% Dec 31, 2025
10 CREF Total Global Stock Account R3 349.65K 0.49% ▲ 0.00% Apr 30, 2026

Valuation Metrics

Enterprise Value: $74.23M
Trailing P/E: 0.00
Forward P/E: 0.00

Financial Highlights

Market Cap: $212.49M
EBITDA: $-106.03M
Book Value: $4.01
Earnings/Share: $-1.24
Profit Margin: 0.00%
Operating Margin: 0.00%
ROA (TTM): -17.10%
ROE (TTM): -30.07%
Revenue (TTM): $385.00
Revenue/Share (TTM): $0.00
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 0.00%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

Financial Ratios

Balance Sheet (Yearly)

Financial Ratios

Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2025-12-31 12.69x 0.02x 0.23x N/A -0.07x
2024-12-31 14.45x 0.01x 0.19x N/A -0.06x
2023-12-31 10.85x 0.02x 0.28x N/A -0.05x
2022-12-31 16.36x 0.01x 0.21x -21.29x -0.04x
2021-12-31 18.99x 0.01x 0.08x -40.96x -0.03x
2020-12-31 36.10x 0.00x 0.05x -164.56x -0.03x
2019-12-31 4.56x -0.06x 1.53x -47.25x -0.08x
2018-12-31 3.96x 0.00x 1.56x N/A 0.00x

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about NKTX.US!